<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801125</url>
  </required_header>
  <id_info>
    <org_study_id>ELN51-309-503</org_study_id>
    <secondary_id>CD FACTOR</secondary_id>
    <nct_id>NCT00801125</nct_id>
  </id_info>
  <brief_title>Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy</brief_title>
  <official_title>A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety, tolerability and clinical benefit of&#xD;
      TYSABRI® (natalizumab) in patients with moderately to severely active Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study sponsor decided to withdraw the current study prior to enrollment of first participant.&#xD;
  </why_stopped>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion (%) achieving a clinical response at Week 12, defined as a reduction in the CDAI score from baseline (Week 0) of ≥ 70 points.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) achieving a clinical remission at each visit, defined as a CDAI score &lt; 150</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion achieving clinical response at Week 4 and Week 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion achieving a ≥ 100 point decrease in baseline (Week 0) CDAI score at each visit</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Crohn's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>natalizumab</intervention_name>
    <other_name>TYSABRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients must be able and willing to give written informed consent and to comply&#xD;
             with the requirements of this study protocol;&#xD;
&#xD;
          2. All patients must be CD TOUCH™ Prescribing Program enrolled;&#xD;
&#xD;
          3. Male or female patients, ≥ 18 years of age;&#xD;
&#xD;
          4. Patients with at least a 3-month history of CD;&#xD;
&#xD;
          5. Patients with clinical evidence of active (symptomatic) CD based on clinical history&#xD;
             and radiologic or endoscopic findings within the previous 36 months. Patients with&#xD;
             active disease following surgical resection must have radiological or endoscopic&#xD;
             confirmation of CD post-surgery;&#xD;
&#xD;
          6. Patients must have evidence of active inflammation measured by CRP &gt;2.87mg/L at the&#xD;
             Screening visit;&#xD;
&#xD;
          7. Subjects must have a CDAI score ≥ 220 and ≤ 450 at Week 0;&#xD;
&#xD;
          8. Female patients must utilize a highly effective method of birth control throughout the&#xD;
             study and for 3 months after study completion, or female patients must not be of&#xD;
             childbearing potential, defined as postmenopausal at least two years, or surgically&#xD;
             sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy);&#xD;
&#xD;
          9. Initial treatment with an approved anti-TNF-α therapy, specifically infliximab,&#xD;
             adalimumab, or certolizumab, who had either a primary or secondary treatment failure,&#xD;
             or intolerance, to those agents;&#xD;
&#xD;
               1. A primary treatment failure is defined as one of the following:&#xD;
&#xD;
                    -  The minimal requirement for a primary treatment failure to infliximab is&#xD;
                       defined as failure to respond to an induction regimen of 5 mg/kg at weeks 0,&#xD;
                       2, and 6;&#xD;
&#xD;
                    -  The minimal requirement for a primary treatment failure to adalimumab is&#xD;
                       defined as failure to respond to an induction regimen of 160 mg at week 0,&#xD;
                       and 80 mg at week 2;&#xD;
&#xD;
                    -  The minimal requirement for a primary treatment failure to certolizumab is&#xD;
                       defined as a failure to respond to an induction regimen of 400 mg at weeks&#xD;
                       0, 2, and 4;&#xD;
&#xD;
               2. Secondary failures to a single anti-TNF-α agent is defined as:&#xD;
&#xD;
                    -  experienced clinical benefit in the opinion of the investigator, but lost&#xD;
                       that benefit over time or discontinued due to an adverse event, and / or;&#xD;
&#xD;
                    -  experienced clinical benefit in the opinion of the investigator, but are&#xD;
                       unable to be discontinued from concurrent oral corticosteroid therapy (i.e.&#xD;
                       ≥ 10 mg/day of prednisone/prednisolone or equivalent).&#xD;
&#xD;
               3. Secondary failures to two anti-TNF-α agents is defined as:&#xD;
&#xD;
                    -  experienced clinical benefit to their initial anti-TNF-α agent in the&#xD;
                       opinion of the investigator, lost that benefit over time or discontinued due&#xD;
                       to an adverse event, and failed to regain clinical benefit following the&#xD;
                       administration of a standard induction protocol to a second anti-TNF-α&#xD;
                       agent; and/or;&#xD;
&#xD;
                    -  experienced clinical benefit in the opinion of the investigator, but are&#xD;
                       unable to be discontinued from concurrent oral corticosteroid therapy (i.e.&#xD;
                       ≥ 10 mg/day of prednisone/prednisolone or equivalent).&#xD;
&#xD;
         10. Intolerance is defined as an inability to tolerate additional administration of an&#xD;
             agent due to acute or delayed reactions, as defined by the investigator;&#xD;
&#xD;
         11. Adequate cardiac, renal and hepatic function as determined by principal investigator&#xD;
             and demonstrated by screening laboratory evaluations, questionnaires, and physical&#xD;
             examination results that are within normal limits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of childbearing potential unless surgically sterile or using adequate&#xD;
             contraception (IUD, oral or depot contraceptive, or barrier plus spermicide), and&#xD;
             willing and able to continue contraception for 3 months after the last infusion of&#xD;
             study drug (i.e., up to Week 20). Women using oral contraception must have started&#xD;
             using it at least 2 months prior to enrollment;&#xD;
&#xD;
          2. Women who are pregnant or breastfeeding;&#xD;
&#xD;
          3. Prior treatment with TYSABRI® (natalizumab) (also referred to as Antegren™ in previous&#xD;
             clinical trials);&#xD;
&#xD;
          4. Symptoms suggestive of intestinal stricture or obstruction;&#xD;
&#xD;
          5. History of cancer or lymphoproliferative disease other than a successfully and&#xD;
             completely treated squamous cell or basal cell carcinoma of the skin;&#xD;
&#xD;
          6. Patients with a history of Listeria or human immunodeficiency virus (HIV) or a history&#xD;
             of previously untreated TB;&#xD;
&#xD;
          7. Patients who have had surgical bowel resections in the past 2 weeks or are planning&#xD;
             any resection within 4 weeks of starting the study medication;&#xD;
&#xD;
          8. Patients who do not meet any of the following criteria regarding baseline medications&#xD;
             for CD (Please note that the term &quot;Week 0&quot; below refers to the exact day of the&#xD;
             baseline visit):&#xD;
&#xD;
               1. Baseline use of anti-tumor necrosis factor (anti-TNF-α) therapy, or previous use&#xD;
                  of all three approved agents, is not permitted;&#xD;
&#xD;
               2. Baseline use of azathioprine (AZA), 6 mercaptopurine (6MP) / 6 thioguanine (6TG)&#xD;
                  / methotrexate (MTX) is not permitted;&#xD;
&#xD;
               3. Baseline use of any other immunosuppressant (e.g., tacrolimus, cyclosporin,&#xD;
                  mycophenolate mofetil or leflunomide) is not permitted;&#xD;
&#xD;
               4. Experimental agents must have been discontinued at least 4 weeks prior to Week 0,&#xD;
                  or for a period equivalent to 5 half-lives (t½) of the agent (whichever is&#xD;
                  longer);&#xD;
&#xD;
               5. Any baseline 5-Aminosalicylate (5 ASA) compounds or antibiotics are permitted and&#xD;
                  if used must be continued at a stable dose during the trial;&#xD;
&#xD;
               6. Any baseline 5-Aminosalicylate (5 ASA) compounds or antibiotics must have been&#xD;
                  administered at a stable dose for a minimum of 4 weeks prior to Week 0;&#xD;
&#xD;
               7. Any baseline use of budesonide must have been administered at a stable dose for a&#xD;
                  minimum of 2 weeks prior to Week 0;&#xD;
&#xD;
               8. For oral steroids other than budesonide, patients must have been at a stable dose&#xD;
                  for a minimum of 2 weeks prior to Week 0;&#xD;
&#xD;
          9. Patients likely to require emergency surgery for persistent intestinal obstruction,&#xD;
             bowel perforation, uncontrolled bleeding or abdominal abscess infection, and patients&#xD;
             who have undergone bowel surgery, including resections, within the 3 months prior to&#xD;
             Week 0;&#xD;
&#xD;
         10. Patients who have a colostomy, ileostomy, or colectomy with ileorectal anastomosis;&#xD;
&#xD;
         11. Ileal resections resulting in clinically relevant short bowel syndrome, in the opinion&#xD;
             of the Investigator;&#xD;
&#xD;
         12. Patients who are receiving or have received nasogastric/nasoenteric tube feeding, an&#xD;
             elemental diet, or total parenteral nutrition (TPN) within the 2 weeks prior to Week&#xD;
             0;&#xD;
&#xD;
         13. Patients with a chest X-ray suggestive of pulmonary infection at screening;&#xD;
&#xD;
         14. Patients with a history of clinically significant and/or persistent gastrointestinal&#xD;
             disorder (other than CD), cardiovascular, renal, hepatic, neurological,&#xD;
             dermatological, immunological, major psychiatric (including drug or alcohol abusers),&#xD;
             or hematological illness;&#xD;
&#xD;
         15. Patients with any laboratory tests considered clinically significant at screening;&#xD;
&#xD;
         16. Patients whose symptoms are likely caused by factors other than inflammatory CD,&#xD;
             including infection, irritable bowel syndrome (IBS), or ulcerative colitis (UC);&#xD;
&#xD;
         17. Patients who will be unavailable for the duration of the trial, likely to be&#xD;
             noncompliant with the protocol, or who are felt to be unsuitable by the Investigator&#xD;
             for any other reason;&#xD;
&#xD;
         18. Patients who have do not have evidence of active inflammation.&#xD;
&#xD;
         19. Patients with active opportunistic infection or history of opportunistic infection in&#xD;
             the last 6 month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

